Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.43 |
| ▸ | MEN1 | O00255 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | CACNA1I | Q9P0X4 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.40 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.39 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18838350 | 0.94 | KMT2A (0.44) | KMT2AMEN1ALDH1A1LMNAHTT | |
| SCHEMBL18838394 | 0.88 | LMNA (0.43) | KMT2AMEN1ALDH1A1LMNAHTT | |
| SCHEMBL18860345 | 0.86 | CACNA1I (0.59) | CACNA1ICYP2D6CACNA1HCACNA1G | |
| SCHEMBL18860331 | 0.85 | CACNA1I (0.45) | KMT2AALDH1A1LMNACACNA1ICACNA1H | |
| SCHEMBL18860279 | 0.85 | CARM1 (0.46) | KMT2AMEN1CACNA1ICARM1PRMT6 | |
| SCHEMBL18838432 | 0.81 | CYP2D6 (0.43) | KMT2AMEN1ALDH1A1CYP2D6CARM1 | |
| SCHEMBL18860275 | 0.80 | DRD4 (0.54) | KMT2AMEN1LMNASMN1; SMN2CYP2D6 | |
| SCHEMBL18860180 | 0.79 | CACNA1I (0.61) | CACNA1ICYP2D6CACNA1HCACNA1G | |
| SCHEMBL18838359 | 0.79 | CACNA1I (0.61) | CACNA1ICYP2D6CACNA1HCACNA1G | |
| SCHEMBL18860178 | 0.79 | CACNA1I (0.61) | CACNA1ICYP2D6CACNA1HCACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | KMT2A 2232/4885MEN1 2540/4885ALDH1A1 2756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.